Alzheimer's Assocation Research only
All of
  • Go to
  • Research Center
  • AAIC
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2015

To view an abstract, select an author from the vertical list on the left.

2015 Grants - Feng

Development of New Therapeutic Reagents for Alzheimer’s Disease

Liang Feng, Ph.D.
Stanford University
Stanford, California

2015 New Investigator Research Grant

Can novel drugs be developed that inhibit the production of toxic beta-amyloid without having unacceptable side effects?

A focus of research into understanding and potentially treating Alzheimer’s disease is beta-amyloid, a protein fragment that may be toxic to nerve cells and can accumulate into clumps called plaques, a hallmark of Alzheimer’s disease. Beta-amyloid is produced from its parent protein by the cutting action of a series of proteins that function as molecular scissors. The protein responsible for the final step of producing beta-amyloid is known as gamma-secretase.

Scientists have developed numerous compounds that inhibit gamma-secretase. However, because gamma-secretase has other important functions, these potential drug candidates have had unacceptable side effects. Recently, however, a few compounds have been discovered that inhibit the ability of gamma-secretase to produce beta-amyloid, but not interfere with its other normal functions. Unfortunately, these drug candidates have not yet been potent enough or specific enough to be used as effective treatments.

Research Plan
Liang Feng, Ph.D., and colleagues have proposed a series of studies to develop novel molecules and test them to determine those that may modulate the activity of gamma-secretase. Specifically, the team will determine if they can modulate gamma-secretase in a way that reduces its production of toxic beta-amyloid without interfering with its other normal functions. They will perform a series of studies in cells growing in laboratory dishes to test molecules that can alter and “lock” gamma-secretase into a shape that cannot produce beta-amyloid but still allows other essential functions.

These studies represent the first steps in understanding how to modulate the activity of gamma-secretase to prevent or slow the production of toxic beta-amyloid in the brain. The results of these studies could lead to the development of novel therapies to prevent, halt or slow Alzheimer’s disease.

Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.